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Abstract The reduced bone mineral density (BMD) observed in
osteoporosis results, in part, from reduced activity of bone-
forming osteoblasts. We examined the effect of peroxisome
proliferator-activated receptor (PPAR) activators on MC3T3-
E1 preosteoblast maturation. Activators of PPARK, N and Q
induced alkaline phosphatase activity, matrix calcification and
the expression of osteoblast genes as determined by reverse
transcriptase-polymerase chain reaction. However, at relatively
high concentrations of the specific PPARQ ligands, ciglitazone
and troglitazone, maturation was inhibited. PPARK, N and Q1
were expressed in MC3T3-E1 cells. PPARQ1 mRNA and protein
levels were induced early during osteoblastic maturation. We
speculate that endogenous and pharmacological PPAR activa-
tors may affect BMD by modulating osteoblastic maturation.
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1. Introduction
Osteoporosis a¡ects an estimated 25 million people in the
USA with fractures as the most prominent clinical conse-
quence [1,2]. The reduction in bone mineral density (BMD)
results, in part, from reduced activity of bone-forming osteo-
blasts [3]. Osteoblasts are derived from mesenchymal precur-
sor cells. The mechanisms directing the cells along an osteo-
blastic lineage and the processes driving maturation are not
established, although a multitude of biological factors and
several key transcription factors have been identi¢ed [4^7].
Novel members of the nuclear hormone receptor superfamily,
the peroxisome proliferator-activated receptors (PPARs), were
recently implicated in the modulation of the relative propor-
tion of bone cell production by the marrow stroma [7,8].
Three PPARs are currently known, PPARK, PPARN and
PPARQ. Each has a speci¢c tissue distribution [9], although all
types have been shown to be expressed in rat bone tissue [10].
PPARs are ligand-activated transcription factors that hetero-
dimerize with the retinoid X receptor K and bind to speci¢c
sequences in the promoters of target genes [9]. Ligands are
semi-selective for the various PPARs depending on the con-
centration and cell type [11]. Fatty acids and certain prosta-
glandin metabolites, particularly of the A and J series [12^14],
are potential endogenous ligands for the PPARs whereas the
insulin-sensitizing thiazolidinediones, including ciglitazone
(CIG), troglitazone (TRO) and rosiglitazone (ROS), are
highly speci¢c ligands for PPARQ [15].
Diascro et al. [16], Nuttall et al. [17] and Lecka-Czernik et
al. [8] have recently shown an inhibitory e¡ect of PPARN and/
or PPARQ on the osteoblastic di¡erentiation of various pre-
cursor cells or cell lines, concomitant with the promotion of
adipocytic di¡erentiation using relatively high concentrations
of PPAR activators or PPARQ overexpression. However,
prostaglandin metabolites of the J and A series, at concentra-
tions appropriate for PPAR activation (10 WM), were shown
to induce osteoblast mineralization in vitro and bone forma-
tion in vivo suggesting that PPARs may have a positive e¡ect
on osteoblastic maturation [18^21]. The precise role of PPARs
in osteoblastic di¡erentiation and maturation is therefore un-
de¢ned. We present data from a study examining the e¡ect of
a variety of PPAR ligands over a range of concentrations on
the osteoblastic maturation of the mouse preosteoblast cell
line, MC3T3-E1. PPARN mRNA was expressed at the highest
level in MC3T3-E1, PPARQ1 and PPARK at relatively lower
levels, and PPARQ2 was not expressed. Activators of PPARK,
N and Q induced the osteoblastic maturation of MC3T3-E1
cells with increased alkaline phosphatase (AP) activity and
matrix calci¢cation. However, at relatively high concentra-
tions of PPARQ activating ligands in particular, maturation
was inhibited. Since PPAR activators are used clinically in the
treatment of type 2 diabetes and hyperlipidemia, it will be of
interest to monitor the BMD of these patients.
2. Materials and methods
PPAR activators were purchased from Caymen Chemical (Ann
Arbor, MI, USA) or Biomol (Plymouth Meeting, PA, USA) and
the anti-PPARQ polyclonal antibody (SA-206), capable of recognizing
both PPARQ1 and Q2, was also from Biomol. PPAR activators were
dissolved in dimethylsulfoxide (DMSO) as 1000-fold stock solutions
and diluted 1000-fold into culture medium. Control cells received an
equivalent amount of DMSO. TRO was kindly supplied by Parke
Davis (Ann Arbor, MI, USA) and ROS was kindly provided by
Smith Kline Beecham (King of Prussia, PA, USA). Radiolabelled
nucleotide triphosphates were obtained from Amersham Life Sciences
(Arlington Heights, IL, USA).
2.1. Cell culture
The MC3T3-E1 mouse preosteoblast cell line (Riken Cell Bank,
Japan) was grown in KMEM (Fisher Scienti¢c, Pittsburgh, PA,
USA) containing 10% heat-inactivated fetal bovine serum (FBS, Hy-
clone Labs, Logan, UT, USA) supplemented with sodium pyruvate (1
mM), penicillin (100 U/ml) and streptomycin (100 U/ml) at 5% CO2
and 37‡C. During osteoblastic maturation studies, KMEM containing
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5% FBS was added to con£uent cells supplemented with 25 Wg/ml
ascorbate and 3 mM L-glycerophosphate (osteogenic factors). PPAR
activators were added at con£uence and with subsequent medium
changes (every 3 days). The 3T3-L1 mouse preadipocyte cell line
was obtained from the American Type Culture Collection (ATCC,
Rockville, MD, USA) and cultured in DMEM containing 10%
FBS. Adipocyte di¡erentiation was induced by adding 1 Wg/ml insulin,
0.5 mM isobutylmethylxanthine and 0.25 WM dexamethasone at con-
£uence for 2 days followed by insulin-containing medium every sub-
sequent 2 days.
2.2. AP activity
Cells cultured in 24 well dishes, were washed twice with phosphate-
bu¡ered saline (PBS) and lysed with scraping and sonication in 200 Wl
of lysis bu¡er (0.2% NP40, 1 mM MgCl2). Reaction bu¡er (1 ml, 1:1
v/v 221 alkaline bu¡er: stock substrate solution, Sigma, St. Louis,
MO, USA) was added to an aliquot of cell lysate and the reaction
was incubated at 37‡C for 10^60 min depending on the rate of prod-
uct formation. The reaction was stopped by addition of 1 N NaOH
(12 Wl). The substrate was cleaved by AP to yield a yellow colored
product that was quanti¢ed spectrophotometrically at a wavelength of
405 nm. Results were normalized to total protein determined by the
Bradford protein assay (Bio-Rad Laboratories, Hercules, CA, USA).
2.3. Matrix calci¢cation^calcium determination
Cells were washed thoroughly with PBS and incubated overnight at
room temperature in 0.1 N HCl (100 Wl) to dissolve calcium mineral
from the calci¢ed matrix. Supernatants were collected and the calcium
level determined using the o-cresolphthalein complexone method (Sig-
ma kit, Procedure #587, Sigma). The cells were washed again with
PBS and protein dissolved in 0.1 N NaOH/0.1% sodium dodecyl sul-
fate (SDS) (200 Wl) overnight at room temperature. Protein content
was determined by the Bradford assay and was used to normalize the
calcium data.
2.4. Western blot
Cell nuclear extracts were prepared as described by Osborn et al.
[22]. Protein (25 Wg) was fractionated by SDS^polyacrylamide gel
electrophoresis on a mini-gel apparatus (Novex, San Diego, CA,
USA) and then transferred to nitrocellulose. Blots were blocked
with 5% non-fat skimmed milk in PBS at room temperature for 2 h
and probed for 1 h at room temperature with anti-PPARQ polyclonal
antibody (1:2000 dilution). Blots were washed six times for 5 min in
PBS containing 0.3% Tween 20 and incubated for 1 h with goat anti-
rabbit secondary antibody conjugated to horseradish peroxidase.
Blots were extensively washed and developed using the ECL system
(Amersham).
2.5. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA (2 Wg) was reverse-transcribed using a standard proto-
col as described previously [23]. PCR was performed using 1 Wl of
cDNA, 25 ng of each primer (synthesized by Gibco BRL), 17.5 WM
dNTPs, 1.5 WCi [K-32P]dCTP and 0.40 U of Pfu polymerase (Strata-
gene) in a 10 Wl reaction volume containing 1UPfu bu¡er (Stratagene)
with a Perkin-Elmer Gene Amp PCR System 2400. The sense and
antisense primers 5P-CGACAAGTGTGATCGGAGCTGCAAG-3P
and 5P-GTTGAAGTTCTTCAGGTAGGCTTC-3P ; 5P-GGCCAAC-
GGCAGTGGCTTCGTC-3P and 5P-GGCTGCGGCCTTAGTACA-
TGTCCT-3P ; 5P-TTCTGACAGGACTGTGTGACAG-3P and 5P-AT-
AAGGTGGAGATGCAGGTTC-3P ; 5P-GCTGTTATGGGTGAAA-
CTCTG-3P and 5P-ATAAGGTGGAGATGCAGGTTC-3P were used
for ampli¢cation of PPARK, N, Q1 and Q2 producing bands of 226,
478, 354 and 350 bp, respectively. The sense and antisense primers 5P-
CCTAAGGCCAACCGTGAAAAG-3P and 5P-TCTTCATGGTGCT-
AGGAGCCA-3P ; 5P-CTTGCTGGTGGAAGGAGGCAGG-3P and
5P-CACGTCTTCTCCACCGTGGGTC-3P ; 5P-CTCGGGTGTAAC-
AGCTAGCTAC-3P and 5P-CGTTCAGAAGGACAGCTGTCTG-
3P ; 5P-CTCTGTCTCTCTGACCTCACAG-3P and 5P-GGAGCTGC-
TGTGACATCCATAC-3P were used for ampli¢cation of L-actin, AP,
bone sialoprotein (BSP) and osteocalcin (OC) producing bands of
645, 393, 383 and 359 bp, respectively. Each cycle consisted of 96‡C
45 s, 62‡C 45 s, 72‡C 2 min, for various cycle numbers depending on
the gene abundance, terminating in 72‡C for 5 min. The PCR reaction
products were electrophoresed on 6% polyacrylamide non-denaturing
gels that were subsequently dried, and exposed to X-ray ¢lm. For
semi-quantitative PCR, the linear range of ampli¢cation was ¢rst
established and PCR cycles chosen to be within that range. Genes
of interest were compared to L-actin or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, ampli¢ed as previously described [23])
which served as normalizing controls.
2.6. Transient transfection
Cells were plated in 12 well dishes at 50% con£uence and transiently
transfected with a total of 5 Wg of plasmid DNA/well using the MBS
transfection kit (Stratagene). Transfections contained 2 Wg of the re-
porter plasmid, 2 Wg of CMV-L-galactosidase plasmid and 1 Wg of
carrier DNA. The heterologous promoter^reporter gene construct
consisted of 110 bp (3471 to 3581) of the acyl CoA oxidase pro-
moter. This region contains a single PPAR response element (PPRE),
capable of interaction with all of the PPARs. The PPRE is upstream
of the rabbit L-globin minimal promoter (bp 3109 to +10), which
provides the necessary elements for basal transcription, and is hooked
up to a luciferase reporter gene (kind gift of Dr. Jonathon Tugwood,
Zeneca Central Toxicology Laboratory, Cheshire, UK) [24]. Follow-
ing transfection, the cells were incubated in KMEM containing 5%
charcoal-stripped FBS (which removes potential PPAR activators) in
the absence or presence of ROS (2.5 WM), carbaprostacyclin (CPC,
Fig. 1. PPAR expression in MC3T3-E1 cells. (A) RT-PCR of total
RNA from MC3T3-E1 cells at di¡erent days post con£uence (day
0) cultured in medium supplemented with 25 Wg/ml ascorbate (asc)
and 3 mM L-glycerophosphate (L-gp) (osteogenic medium). The
lower panel shows the level of expression of L-actin and PPARQ1 as
a function of PCR cycle number for a single sample. (B) Asc and
L-gp induced PPARQ1 mRNA in MC3T3-E1 cells. (C) Western blot
analysis for PPARQ in nuclear extracts isolated from 3T3-L1 preadi-
pocytes (PreAd), mature adipocytes (a positive control for PPARQ1
and Q2 expression, Ad) and MC3T3-E1 cells at day 2 post con£u-
ence (upper panel) and days 0, 4 and 8 post con£uence (lower pan-
el) cultured in osteogenic medium (asc+L-gp). PPARQ2 was detected
in the mature adipocytes but not the preadipocytes as expected. A
third band of approximately 65 kDa was also detected (*). The mi-
gration of the molecular weight marker of 49.5 kDa is indicated.
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2 WM) or Wyeth 14643 (WY, 10 WM) for 40 h. Cells were lysed and
luciferase and L-galactosidase activities determined as previously de-
scribed [25]. Luciferase activity was normalized for transfection e⁄-
ciency using the L-galactosidase activity.
2.7. Statistics
Computer-assisted statistical analyses were performed using the
ANOVA program, and P values calculated using Fisher’s PLSD sig-
ni¢cance test. Di¡erences were considered signi¢cant at P6 0.05.
3. Results
3.1. PPAR expression in MC3T3-E1 cells
PPARK, N and Q are ligand-activated transcription factors
of the nuclear hormone receptor superfamily. PPARQ has two
isoforms, a result of di¡erent promoter usage and alternative
splicing, that are termed Q1 and Q2. The expression of the
latter is predominantly restricted to adipose tissue. RT-PCR
showed expression of PPARK, N and Q1 mRNA in MC3T3-E1
utilizing 30, 18 and 28 cycles, respectively (Fig. 1A, upper
panel). PPARQ1 mRNA was ¢rst detectable at 26 cycles by
RT-PCR (Fig. 1A, lower panel), however, PPARQ2 mRNA
was not detected even up to 35 cycles (data not shown). The
level of expression of PPARQ1 mRNA consistently increased
from day 0 to 6 and declined from day 6 to 30 in culture,
whereas the expression levels of PPARN and L-actin (15
cycles) mRNA remained relatively unchanged throughout
the culture period (Fig. 1A, upper panel). Expression levels
of PPARK were more variable, in some experiments expres-
sion increased early in culture (Fig. 1A, upper panel), whereas
in others expression was unchanged with culture time (Fig.
1B). Interestingly, PPARQ1 mRNA, but not PPARN (or
PPARK), was induced by the presence of osteogenic factors,
ascorbate and L-glycerophosphate, in the medium (Fig. 1B),
that was similarly observed at the protein level (Fig. 1C). A
Fig. 2. MC3T3-E1 cells express functional PPARs. MC3T3-E1 cells
were transiently co-transfected with a PPRE^luciferase construct
and a CMV-L-galactosidase plasmid and treated with the PPAR ac-
tivators WY (10 WM), ROS (2.5 WM) and CPC (2 WM) for 40 h.
Cells were lysed and luciferase activity determined and normalized
to L-galactosidase activity. The luciferase/L-galactosidase (Lucif./
Lgal.) value for control cells (Con, DMSO-treated) was set at 100%.
Values are presented as mean þ S.D., $: P6 0.02, @: P6 0.001,
n = 3. The results are representative of three experiments.
Fig. 3. E¡ect of PPAR activators on AP activity. AP activity was determined in MC3T3-E1 cells cultured in 24 well plates for 6 days post con-
£uence (day 0) in osteogenic medium in the absence (0 WM) or presence of various doses of the PPAR activators. The AP activity normalized
to cell protein obtained from cells without added PPAR activator (0 WM, DMSO-treated) was set at 100%, corresponding to 35^45 U/mg pro-
tein depending on the particular experiment. Values are presented as mean þ S.D., L : P6 0.05, #: P6 0.002, *: P6 0.0001, n = 4. The results
are representative of 2^3 experiments each performed in quadruplicate.
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protein band of approximately 65 kDa was also detected that
was regulated similarly to PPARQ1, however, the identity of
the protein is unknown (Fig. 1C). Northern blot analysis of
MC3T3-E1 RNA detected the expression of PPARN mRNA
at a similar level to that expressed in mature 3T3-L1 adipo-
cytes, but was not sensitive enough to detect PPARK, PPARQ1
or Q2 (data not shown).
To determine whether the PPARs in MC3T3-E1 cells were
functional, a PPRE^luciferase promoter^reporter construct
containing 110 bp of the acyl CoA oxidase promoter, harbor-
ing a binding site for PPARs [24], was transiently transfected
into MC3T3-E1 cells. The cells were then incubated in me-
dium supplemented with PPAR activators. Expression of the
luciferase reporter was induced signi¢cantly, but only mod-
estly, in multiple experiments in the presence of 2.5 WM
ROS (2.05 þ 0.64-fold vs. control, P6 0.02, n = 3), a speci¢c
PPARQ activating ligand, and 2 WM CPC (3.34 þ 0.35-fold,
P6 0.001, n = 3), a PPARK and N activator, but not by 10
WM WY (1.29 þ 0.28-fold, n.s., n = 3), a speci¢c PPARK acti-
vator at 10 WM (Fig. 2). Together with the mRNA and pro-
tein expression data above, these results indicate that MC3T3-
E1 cells expressed functional PPARN, relatively low levels of
functional PPARQ1 and perhaps PPARK, and no PPARQ2.
3.2. E¡ect of PPAR activators on osteoblastic maturation
Incubation of MC3T3-E1 cells with the PPAR activators
WY, CPC, or the speci¢c Q activators TRO and CIG, dose
dependently induced AP activity, an early marker of osteo-
blastic maturation (Fig. 3A^D). Reduced AP activity was ob-
served however at higher PPAR activator concentrations, par-
Fig. 4. E¡ect of PPAR activators on matrix calci¢cation. (A)
MC3T3-E1 cells were cultured in 12 or 24 well plates for approxi-
mately 30 days post con£uence (day 0) in osteogenic medium in the
absence (Con) or presence of PPAR activators: WY, PGE, PGJ,
2Bp, CPC and Bez, at the stated concentrations, and (B) increasing
doses of CIG. Calcium content of the matrix was determined as de-
scribed in Section 2 and normalized to protein content. The normal-
ized value obtained from cells incubated under control conditions
(Con, DMSO-treated) was set at 100%, corresponding to 4.77 þ 0.41
Wg calcium/Wg protein. The results are presented as mean þ S.D., *:
P6 0.0001, n = 3. The results are representative of two experiments
each performed in triplicate. (C) AP and GAPDH mRNA expres-
sion was determined by RT-PCR of total RNA isolated from
MC3T3-E1 cells 6 days post con£uence cultured in osteogenic me-
dium in the absence (Control) or presence of 5 WM CIG (5 WM).
Fig. 5. E¡ect of PPAR activators on osteoblast gene expression as
determined by RT-PCR. (A) Time course of expression. PCR cycles
of 24, 22, 30 and 18 were utilized for AP, BSP, OC and GAPDH,
respectively. (B) RT-PCR of total RNA isolated from MC3T3-E1
cells cultured for 6 days as above in the absence (Con) or presence
of PPAR activators at the indicated concentrations (WM).
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ticularly for TRO and CIG (Fig. 3C,D). PPAR activators
including WY, 15-deoxy-v12;14-prostaglandin J2 (PGJ, an K
and Q activator), 2-bromopalmitate (2Bp, an K, N and Q acti-
vator), CPC and beza¢brate (Bez, an K and N activator) in-
duced matrix calci¢cation, a late marker of osteoblastic mat-
uration (Fig. 4A). Prostaglandin E2 (PGE, no PPAR
activation ability) had no e¡ect on AP activity (data not
shown) or matrix calci¢cation (Fig. 4A). CIG dose depend-
ently induced matrix calci¢cation to a maximal e¡ect at 2.5
WM, but inhibited this process at concentrations higher than
10 WM (Fig. 4B). The induced osteoblastic maturation ob-
served with relatively low concentrations of CIG was consis-
tent with an increase in AP steady state mRNA expression in
MC3T3-E1 cells treated with 5 WM CIG for 6 days as deter-
mined by RT-PCR (Fig. 4C).
During osteoblastic maturation, speci¢c genes are di¡eren-
tially expressed both temporally and as a result of exposure of
the cells to stimulatory or inhibitory physiological factors
such as hormones [26]. The temporal expression of AP, BSP
and OC mRNA level was determined by RT-PCR for
MC3T3-E1 cells cultured from day 0 to 30 in medium supple-
mented with osteogenic factors (Fig. 5A). Very low levels of
expression of AP and BSP were evident at day 0, but levels
rose to peak between day 6 and 12 in culture and then de-
clined slightly from day 18 to 30 in culture. OC mRNA levels
were relatively constant throughout the culture period (Fig.
5A). On the basis of these results, the level of expression of
each osteoblast gene was measured following 6 days in culture
in medium supplemented with various PPAR activators. Most
dramatically, 10 WM CIG inhibited the expression of AP and
BSP mRNA levels (Fig. 5B). A notable induction in expres-
sion levels for BSP and OC mRNA was observed with the
other PPAR activators, but not PGE (Fig. 5B), indicating that
the promotion of osteoblastic maturation by PPAR activators
in MC3T3-E1 cells correlated with increased expression of
osteoblast genes.
4. Discussion
In this study, we have demonstrated the expression and
function of PPARs in the mouse preosteoblastic cell line,
MC3T3-E1. PPAR activators induced osteoblastic maturation
of the MC3T3-E1 cells, however, at relatively higher concen-
trations, the PPARQ ligands CIG and TRO signi¢cantly in-
hibited this process.
Inhibition of osteoblastic di¡erentiation by PPAR activa-
tors has been observed previously but either utilized relatively
high concentrations of PPARQ ligands (5 WM TRO, 5 WM
ROS) or required the induced expression of endogenous
PPARQ2 or ectopic PPARQ2 overexpression [8,16,17]. In the
present experiments, PPARQ2 was not detected in MC3T3-E1
cells, even following treatment with various combinations of
adipogenic factors (data not shown). This lack of adipogenic
di¡erentiation suggests that MC3T3-E1 cells have reached a
level of mesenchymal lineage commitment beyond that of tra-
becular bone cells and marrow stromal cells, which retain
multipotentiality.
E¡ects of relatively low concentrations of PPARQ activators
or e¡ects of PPARK and N activators on osteoblastic matura-
tion have not been previously reported. We observed en-
hanced osteoblastic di¡erentiation of MC3T3-E1 cells treated
with relatively low concentrations of the PPARQ speci¢c li-
gand, CIG (6 5 WM). Furthermore, activators of PPARK
and N induced osteoblastic maturation with increased AP ac-
tivity and matrix calci¢cation. Consistent with this, these ac-
tivators also induced AP, BSP and OC steady state mRNA
levels. Consistent with the inhibition of osteoblastic matura-
tion at 10 WM CIG, the mRNA levels of AP and BSP, but not
OC, were dramatically reduced. The lack of inhibition of OC
mRNA expression indicates that OC is less sensitive to this
negative regulation than AP or BSP. Nevertheless, the loss of
AP and BSP was su⁄cient to prevent matrix calci¢cation.
The induction in expression of PPARQ1 mRNA and protein
during osteoblastic maturation of MC3T3-E1 cells and the
induction in PPARQ1 expression by osteogenic factors is pre-
liminary evidence of a role for this PPAR in the maturation
process. Identi¢cation of a direct interaction between PPAR
and the promoters of osteoblast genes adds further prelimi-
nary evidence. A putative PPAR binding site was identi¢ed in
the promoter of the osteopontin gene [27], and co-transfection
of BSP^luciferase and OC^luciferase promoter^reporter con-
structs with a PPARN expression plasmid in osteoblastic cells
regulated luciferase activity [28].
Potential speculative mechanisms for PPAR e¡ects relate to
direct PPAR modulation of osteoblast gene transcription and
e¡ects on cell cycle regulation [29], and apoptosis [30]. PPAR
induces expression of the glucose transporter, GLUT4, during
adipocytic di¡erentiation. Recently, GLUT4 was shown to be
required for bone growth, perhaps related to increased energy
requirements during matrix synthesis [31]. Since PPARs are
known to regulate genes involved in lipid biosynthesis and
lipid transport in adipocytes [9], they may in£uence the for-
mation of phospholipid-rich matrix vesicles in osteoblasts that
are required for matrix calci¢cation.
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